Ocera Therapeutics, Inc.
OCRX
OCRX was delisted on the 8th of December, 2017.
10 hedge funds and large institutions have $5.87M invested in Ocera Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.
84% more capital invested
Capital invested by funds: $3.19M → $5.87M (+$2.68M)
23% less funds holding
Funds holding: 13 → 10 (-3)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$838K |
| 2 |
Jennison Associates
New York
|
+$257K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$113K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$63.6K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$10.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$72.6K |
| 2 |
Renaissance Technologies
New York
|
-$52K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$23K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$20K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$19.5K |
OCRX Hedge Fund Activity: Q3 2013 in Review
10 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics, Inc. (OCRX) for Q3 2013, worth a combined $5.87M — up 84% from $3.19M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of OCRX and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $838K. The largest seller was RA Capital Management, cutting an estimated $72.6K.
- 10 institutional investors held Ocera Therapeutics, Inc. (OCRX) as of Q3 2013, down from 13 in Q2 2013.
- Funds reported $5.87M of Ocera Therapeutics, Inc. stock for Q3 2013, up 84% quarter-over-quarter.
- 3 funds opened new Ocera Therapeutics, Inc. positions in Q3 2013 and 6 closed out, a net change of -3 holders.
- The largest Ocera Therapeutics, Inc. buyer in Q3 2013 was Vanguard Group, an estimated $838K added.
- The largest Ocera Therapeutics, Inc. seller in Q3 2013 was RA Capital Management, an estimated $72.6K sold.
Based on aggregated 13F filings for Q3 2013.